In recently published work from Air Force Medical University, analysis of tumor tissues isolated from different patient-derived xenografts revealed significantly increased expression of FXYD5 in the metastatic tumors compared to the primary tumors, and analysis of patient database confirmed significantly elevated expression of FXYD5 in gastric cancer tissues compared to normal gastric tissues.